YAP1

Summary

YAP1 (Yes1 associated transcriptional regulator, HGNC:16262) is a protein-coding gene on chromosome 11q22.1, encoding Transcriptional coactivator YAP1 (P46937). Transcriptional regulator with dual roles as a coactivator and corepressor. It is a selective cancer dependency (DepMap: 27.6% of cell lines).

This gene encodes a downstream nuclear effector of the Hippo signaling pathway which is involved in development, growth, repair, and homeostasis. This gene is known to play a role in the development and progression of multiple cancers as a transcriptional regulator of this signaling pathway and may function as a potential target for cancer treatment. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 10413 — RefSeq curated summary.

At a glance

• Gene–disease (curated): uveal coloboma-cleft lip and palate-intellectual disability (Strong, GenCC)
• GWAS associations: 19
• Clinical variants (ClinVar): 143 total — 3 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 21
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 27.6% of screened cell lines
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• Transcription factor: yes — 10 downstream targets (CollecTRI)
• MANE Select transcript: NM_001130145

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16262
Approved symbol	YAP1
Name	Yes1 associated transcriptional regulator
Location	11q22.1
Locus type	gene with protein product
Status	Approved
Aliases	YAP65, YAP-1
Ensembl gene	ENSG00000137693
Ensembl biotype	protein_coding
OMIM	606608
Entrez	10413

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 15 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000282441, ENST00000345877, ENST00000524575, ENST00000526343, ENST00000526594, ENST00000528834, ENST00000529029, ENST00000531439, ENST00000537274, ENST00000615667, ENST00000629586, ENST00000890964, ENST00000890965, ENST00000890966, ENST00000890967, ENST00000951260, ENST00000951261

RefSeq mRNA: 9 — MANE Select: NM_001130145 NM_001130145, NM_001195044, NM_001195045, NM_001282097, NM_001282098, NM_001282099, NM_001282100, NM_001282101, NM_006106

CCDS: CCDS44716, CCDS53699, CCDS53700, CCDS60944, CCDS60945, CCDS73373, CCDS73374, CCDS8314

Canonical transcript exons

ENST00000282441 — 9 exons

Exon	Start	End
ENSE00001105702	102223622	102223752
ENSE00001292600	102205893	102206074
ENSE00001311988	102186018	102186131
ENSE00001321313	102209517	102209564
ENSE00003638627	102227469	102227581
ENSE00003640769	102114144	102114394
ENSE00003669240	102162456	102162571
ENSE00003850824	102229702	102233424
ENSE00003850849	102110447	102111169

Expression profiles

Bgee: expression breadth ubiquitous, 279 present calls, max score 99.12.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 50.6855 / max 644.6993, expressed in 1461 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
116384	20.1483	1427
116383	12.0853	1423
116389	8.7409	1375
116382	2.5758	1201
116388	1.9993	1010
116385	1.2385	764
116387	1.0505	734
116381	0.9876	666
116394	0.6124	281
116386	0.5532	340

Top tissues by expression

297 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
saphenous vein	UBERON:0007318	99.12	gold quality
germinal epithelium of ovary	UBERON:0001304	98.98	gold quality
cauda epididymis	UBERON:0004360	98.94	gold quality
urethra	UBERON:0000057	98.82	gold quality
seminal vesicle	UBERON:0000998	98.62	gold quality
penis	UBERON:0000989	98.42	gold quality
parietal pleura	UBERON:0002400	98.23	gold quality
esophagus squamous epithelium	UBERON:0006920	98.17	gold quality
superficial temporal artery	UBERON:0001614	97.91	gold quality
pericardium	UBERON:0002407	97.85	gold quality
corpus epididymis	UBERON:0004359	97.81	gold quality
visceral pleura	UBERON:0002401	97.80	gold quality
right coronary artery	UBERON:0001625	97.73	gold quality
gingival epithelium	UBERON:0001949	97.70	gold quality
lower lobe of lung	UBERON:0008949	97.67	gold quality
skin of hip	UBERON:0001554	97.63	gold quality
nipple	UBERON:0002030	97.59	gold quality
endometrium	UBERON:0001295	97.51	gold quality
descending thoracic aorta	UBERON:0002345	97.49	gold quality
vena cava	UBERON:0004087	97.48	gold quality
aorta	UBERON:0000947	97.43	gold quality
popliteal artery	UBERON:0002250	97.43	gold quality
thoracic aorta	UBERON:0001515	97.42	gold quality
tibial artery	UBERON:0007610	97.42	gold quality
mammalian vulva	UBERON:0000997	97.40	gold quality
ascending aorta	UBERON:0001496	97.38	gold quality
synovial joint	UBERON:0002217	97.37	gold quality
gingiva	UBERON:0001828	97.29	gold quality
upper leg skin	UBERON:0004262	97.26	gold quality
artery	UBERON:0001637	97.25	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	16.02
E-MTAB-3929	no	109.88

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

10 targets.

Target	Regulation
BAX	Activation
BMP4	Activation
FSTL3	Activation
SFN
SOX5	Repression
SOX6	Repression
SOX9	Repression
TEAD1	Activation
TEAD2	Activation
WWC1	Activation

Upstream regulators (CollecTRI, top): CREB1, MYT1, MYT1L, TCF3, TCF7L2, TP53, TP63, VEPH1

miRNA regulators (miRDB)

123 targeting YAP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-6772-5P	99.94	67.01	577
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-4760-3P	99.93	70.50	2385

Functional genomics

ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 27.6% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• NMR structures of the YAP65 WW domain and the variant L30 K in complex with the peptides GTPPPPYTVG, N-(n-octyl)-GPPPY and PLPPY and the application of peptide libraries reveal a minimal binding epitope (PMID:11743730)
• YAP is a potential signaling partner of the full-length ErbB4 receptor at the membrane and of the COOH-terminal fragment of ErbB-4 that translocates to the nucleus to regulate transcription (PMID:12807903)
• Yap binds to HNRNPU and regulates its co-activation of Bax transcription (PMID:15096513)
• the minimum binding domain is larger than the latter two strands of the WW domain beta-sheet (PMID:15800888)
• WWOX antagonizes the function of YAP by competing for interaction with ErbB-4 and other targets and thus affect its transcriptional activity. (PMID:16061658)
• Results suggested that YAP65 plays a role in the normal and diseased pancreas. (PMID:16596258)
• WBP-2 and YAP are coactivators for estrogen and progesterone receptor transactivation pathways. (PMID:16772533)
• Results point to a potential oncogenic role for YAP in 11q22-amplified human cancers, and suggest that this signaling pathway regulates both cellular proliferation and apoptosis in mammalian epithelial cells. (PMID:16894141)
• The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. (PMID:17110958)
• the RUNX2 and YAP65 interaction has a novel role in oncogenic transformation that may be mediated by modulation of p21(CIP1) protein expression (PMID:17438369)
• Proline-rich Gla protein 2 may be involved in a signal transduction pathway, the impairment of which may be an unintended consequence of warfarin therapy (PMID:17502622)
• YAP identified as a novel and critical downstream effector of c-Jun-mediated apoptosis following cisplatin treatment (PMID:17823615)
• Delineate a mammalian Hippo signaling pathway that culminates in the phosphorylation of YAP, the mammalian homolog of Yki. Is a potent regulator of organ size, and its dysregulation leads to tumorigenesis. (PMID:17889654)
• findings report that YAP1 increases organ size and causes aberrant tissue expansion (PMID:17980593)
• LATS1 inactivates YAP oncogenic function by suppressing its transcription regulation of cellular genes via sequestration of YAP in the cytoplasm after phosphorylation of YAP. (PMID:18158288)
• Increased YAP protein is associated with esophageal and gastric epithelial tumorigenesis. (PMID:18175224)
• c-Abl directly phosphorylates Yap1 at position Y357 in response to DNA damage. Tyrosine-phosphorylated Yap1 is a more stable protein that displays higher affinity to p73 and selectively coactivates p73 proapoptotic target genes. (PMID:18280240)
• Expression profiling of genes induced by ectopic expression of YAP or by knockdown of LATS1 reveals a subset of the potential Drosophila Hippo pathway targets implicated in epithelial-to-mesenchymal transition. (PMID:18413746)
• This is the first report indicating YAP as a tumor suppressor, revealing its decreased expression in breast cancer as well as demonstrating the functional implications of YAP loss in several aspects of cancer signaling. (PMID:18617895)
• Overexpression of YAP2 in cells promoted apoptosis, whereas the Mst2/Lats1-induced phosphorylation of YAP partially rescued the cells from apoptotic death. (PMID:18640976)
• The modified Yap1 does not co-activate Runx in supporting Itch transcription. The subsequent reduction in the Itch level gives rise to p73 accumulation. (PMID:18701449)
• findings suggest that activation of the Hippo signaling pathway may occur through YAP as part of cell proliferation in normal tissue homeostasis and also might be a frequently activated oncogenic pathway in 3 common malignant tumor types. (PMID:18703216)
• this is the first report of negative regulatory signaling from Merlin to YAP1 in mammalian cells and may shed light on mechanisms of malignant pleural mesothelioma development (PMID:18725387)
• results represent the first demonstration that merlin regulates cell growth in meningioma cells by suppressing YAP (PMID:18953429)
• YAP and TEAD gain of function causes marked expansion of the neural progenitor population, partly owing to their ability to promote cell cycle progression by inducing cyclin D1 and to inhibit differentiation by suppressing NeuroM. (PMID:19015275)
• The existence of a proapoptotic autoregulatory feedback loop between p73, YAP, and the promyelocytic leukemia (PML) tumor suppressor gene, is shown. (PMID:19111660)
• The PDZ-binding motif is necessary for YAP2 localization in the nucleus, for the stabilization of p73, and for promoting apoptosis of HEK293 cells maintained at low concentration of serum. (PMID:19371381)
• Yes-associated protein and survivin have roles in gastric carcinoma and precancerous lesions (PMID:19705503)
• show that YAP-expressing MCF10A breast epithelial cells enhance the proliferation of neighbouring untransfected cells, implicating a non-cell-autonomous mechanism. (PMID:19935651)
• findings implicate YAP1 as a new Shh effector that may be targeted by medulloblastoma therapies aimed at eliminating medulloblastoma recurrence. (PMID:19952108)
• Results strongly suggest that Yap1 plays a role in the regulation of endogenous DeltaNp63alpha levels and is likely to contribute to the regulation of DeltaNp63alpha, in physiological conditions. (PMID:20016275)
• identified CK1delta/epsilon as new regulators of YAP and uncovered an intricate mechanism of YAP regulation (PMID:20048001)
• This data suggests that the phosphorylation of Yap at Ser127 leads to a changed expression of myogenic regulatory factors and cell cycle regulators and is required for C2C12 myoblasts to differentiate into myotubes. (PMID:20153295)
• YAP plays an important role in NSCLC and might be a useful therapeutic target of NSCLC. (PMID:20219076)
• miR-375 is an important regulator of YAP oncogene playing the role in hepatocellular carcinoma development. (PMID:20226166)
• that YAP1 overexpression in primary human keratinocytes blocks clonal evolution and induces cell immortalization, but not malignant transformation. (PMID:20677011)
• YAP function as a tumor suppressor may alternatively be dysregulated by AKT phosphorylation at serine-127 and cytoplasmic sequestration, or by transcriptional repression by DeltaNp63, in different subsets of head and neck squamous cell carcinomas (HNSCCs). (PMID:20729916)
• 14-3-3sigma has been cloned, purified and crystallized in complex with a phosphopeptide from the YAP 14-3-3-binding domain, which led to a crystal that diffracted to 1.15 A resolution. (PMID:20823509)
• data suggest that the amplification and overexpression of YAP1 and VGLL3 could be involved in oncogenesis and progression of soft tissue sarcomas (PMID:20842732)
• translocation of YAP2 to nucleus requires complexation with ZO-2; PDZ domains on both proteins are involved in complex formation; YAP2/ZO-2 complex appears to be involved in cell detachment (PMID:20868367)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Yap1	ENSMUSG00000053110
rattus_norvegicus	Yap1	ENSRNOG00000005933
caenorhabditis_elegans		WBGENE00008748

Paralogs (1): WWTR1 (ENSG00000018408)

Protein

Protein identifiers

Transcriptional coactivator YAP1 — P46937 (reviewed: P46937)

Alternative names: Protein yorkie homolog, Yes-associated protein YAP65 homolog

All UniProt accessions (2): P46937, H0YCI3

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional regulator with dual roles as a coactivator and corepressor. Critical downstream regulatory target in the Hippo signaling pathway, crucial for organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The Hippo signaling pathway core involves a kinase cascade featuring STK3/MST2 and STK4/MST1, along with its regulatory partner SAV1, which phosphorylates and activates LATS1/2 in complex with their regulatory protein, MOB1. This activation leads to the phosphorylation and inactivation of the YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1/2 prevents its nuclear translocation, thereby regulating the expression of its target genes. The transcriptional regulation of gene expression requires TEAD transcription factors and modulates cell growth, anchorage-independent growth, and induction of epithelial-mesenchymal transition (EMT). Plays a key role in tissue tension and 3D tissue shape by regulating the cortical actomyosin network, acting via ARHGAP18, a Rho GTPase activating protein that suppresses F-actin polymerization. It also suppresses ciliogenesis by acting as a transcriptional corepressor of TEAD4 target genes AURKA and PLK1. In conjunction with WWTR1, regulates TGFB1-dependent SMAD2 and SMAD3 nuclear accumulation. Synergizes with WBP2 to enhance PGR activity. Activates the C-terminal fragment (CTF) of ERBB4 (isoform 3). Activates the C-terminal fragment (CTF) of ERBB4 (isoform 3).

Subunit / interactions. Part of a complex when phosphorylated that contains DSG3, PKP1, YAP1 and YWHAG; the complex is required for localization of DSG3 and YAP1 to the cell membrane in keratinocytes. Binds to the SH3 domain of the YES kinase. Binds to WBP1 and WBP2. Binds, in vitro, through the WW1 domain, to neural isoforms of ENAH that contain the PPSY motif. The phosphorylated form interacts with YWHAB. Interacts (via WW domains) with LATS1 (via PPxY motif 2). Interacts with LATS2. Interacts with TEAD1, TEAD2, TEAD3 and TEAD4. Interacts with TP73. Interacts with RUNX1. Interacts with HCK. Interacts (via WW domains) with PTPN14 (via PPxY motif 2); this interaction leads to the cytoplasmic sequestration of YAP1 and inhibits its transcriptional coactivator activity. Interacts (when phosphorylated at Ser-127) with SMAD2, SMAD3 and WWTR1. Interacts with PRRG2 (via cytoplasmic domain). Interacts (via WW domains) with PRRG4 (via cytoplasmic domain). Interacts (phosphorylated) with CLDN18; the interaction sequesters YAP1 away from the nucleus and thereby restricts transcription of YAP1 target genes. Interacts with SMAD1. Interacts with AMOTL2, the interaction is required for ubiquitination of AMOTL2 and localization of YAP1 to tight junctions. Interacts with AMOT isoform 1; the interaction facilitates translocation of YAP1 to the cytoplasm and tight junctions. Interacts (via WW domain 1) with isoform 3 of ERBB4 (via PPxY motif 2). Interacts (via WW domain 1) with isoform 3 of ERBB4 (via PPxY motif 2).

Subcellular location. Cytoplasm. Nucleus. Cell junction. Tight junction. Cell membrane.

Tissue specificity. Increased expression seen in some liver and prostate cancers. Isoforms lacking the transactivation domain found in striatal neurons of patients with Huntington disease (at protein level).

Post-translational modifications. Phosphorylated by LATS1 and LATS2; leading to cytoplasmic translocation and inactivation. Phosphorylated by ABL1; leading to YAP1 stabilization, enhanced interaction with TP73 and recruitment onto proapoptotic genes; in response to DNA damage. Phosphorylation at Ser-400 and Ser-403 by CK1 is triggered by previous phosphorylation at Ser-397 by LATS proteins and leads to YAP1 ubiquitination by SCF(beta-TRCP) E3 ubiquitin ligase and subsequent degradation. Phosphorylated at Thr-119, Ser-138, Thr-154, Ser-367 and Thr-412 by MAPK8/JNK1 and MAPK9/JNK2, which is required for the regulation of apoptosis by YAP1. Phosphorylated in the nucleus by PRP4K; phosphorylation leads to nuclear exclusion. Lactylation by AARS1 promotes nuclear localization and stabilization of YAP1, leading to increased Hippo signaling pathway. Delactylated by SIRT1. Ubiquitinated by SCF(beta-TRCP) E3 ubiquitin ligase.

Disease relevance. Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or impaired intellectual development (COB1) [MIM:120433] An autosomal dominant disease characterized by uveal colobomata, microphthalmia, cataract and cleft lip/palate. Considerable variability is observed among patients, uveal colobomata being the most constant feature. Some patients manifest intellectual disability of varying degree and/or sensorineural, mid-frequency hearing loss. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. The first coiled-coil region mediates most of the interaction with TEAD transcription factors.

Induction. Induced in the hours following cyclic mechanical strain in keratinocytes.

Miscellaneous. Highest expression in ovary and placenta, lowest in skeletal muscle and brain.

Similarity. Belongs to the YAP1 family.

Isoforms (9)

UniProt ID	Names	Canonical?
P46937-1	1, YAP1-2gamma, YAP2L	yes
P46937-2	2, YAP1-2alpha, YAP2
P46937-3	3, YAP1-1beta
P46937-4	4
P46937-5	5, YAP1-1alpha
P46937-6	6, YAP1-1gamma
P46937-7	7, YAP1-1delta
P46937-8	8, YAP1-2beta
P46937-9	9, YAP1-2delta

RefSeq proteins (9): NP_001123617, NP_001181973, NP_001181974, NP_001269026, NP_001269027, NP_001269028, NP_001269029, NP_001269030, NP_006097 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001202	WW_dom	Domain
IPR036020	WW_dom_sf	Homologous_superfamily
IPR051583	YAP1	Family
IPR053819	TEADIR3_omega_loop	Conserved_site

Pfam: PF00397, PF15238

UniProt features (97 total): mutagenesis site 26, modified residue 25, strand 12, region of interest 6, helix 6, splice variant 5, compositionally biased region 4, sequence variant 4, turn 4, domain 2, coiled-coil region 2, chain 1

Structure

Experimental structures (PDB)

41 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
6G6X	X-RAY DIFFRACTION	1.13
3MHR	X-RAY DIFFRACTION	1.15
7O07	X-RAY DIFFRACTION	1.2
6G8K	X-RAY DIFFRACTION	1.25
6G8L	X-RAY DIFFRACTION	1.37
8A8Q	X-RAY DIFFRACTION	1.47
6G8J	X-RAY DIFFRACTION	1.47
4REX	X-RAY DIFFRACTION	1.6
6G8I	X-RAY DIFFRACTION	1.6
6GEI	X-RAY DIFFRACTION	1.65
6HIK	X-RAY DIFFRACTION	1.65
8A8R	X-RAY DIFFRACTION	1.7
6GEC	X-RAY DIFFRACTION	1.7
6GE6	X-RAY DIFFRACTION	1.8
6G8Q	X-RAY DIFFRACTION	1.85
6GE3	X-RAY DIFFRACTION	1.85
6G8P	X-RAY DIFFRACTION	1.9
5OAQ	X-RAY DIFFRACTION	1.95
6GEE	X-RAY DIFFRACTION	1.96
6GE4	X-RAY DIFFRACTION	1.97
6GE5	X-RAY DIFFRACTION	2.05
6Q2X	X-RAY DIFFRACTION	2.1
4RE1	X-RAY DIFFRACTION	2.2
9FZA	X-RAY DIFFRACTION	2.21
6GEG	X-RAY DIFFRACTION	2.23
6GEK	X-RAY DIFFRACTION	2.28
6HIL	X-RAY DIFFRACTION	2.3
8C2F	X-RAY DIFFRACTION	2.3
3KYS	X-RAY DIFFRACTION	2.8
1JMQ	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P46937-F1	58.46	0.02

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (25): 61, 63, 90, 105, 109, 110, 119, 127, 128, 131, 138, 154, 164, 274, 289, 367, 371, 381, 382, 388 …

Mutagenesis-validated functional residues (26):

Position	Phenotype
61	in yap-4sa; prevents phosphorylation by lats1 and lats2, promoting retention in the nucleus; when associated with a-109;
80	no change in interaction with tead4. reduced interaction with tead4 and transforming ability; when associated with a-84
84	reduced interaction with tead4 and transforming ability; when associated with a-80 and a-85.
85	reduced interaction with tead4 and transforming ability; when associated with a-80 and a-84.
86	complete loss of interaction with tead1.
89	complete loss of interaction with tead1.
90	nearly abolished lactylation.
91	complete loss of interaction with tead1.
94	loss of interaction with tead1, tead2, tead3 and tead4. loss of transcriptional coactivation activity towards tead1, tea
95	complete loss of interaction with tead1.
96	loss of interaction with tead1.
109	in yap-4sa; prevents phosphorylation by lats1 and lats2, promoting retention in the nucleus; when associated with a-61;
122	loss of phosphorylation by lats1.
122	significantly decreased phosphorylation at s-127 and decreased interaction with ywhab.
124	loss of phosphorylation by lats1.
127	reduced phosphorylation by lats2, loss of phosphorylation by lats1, loss of interaction with ywhab, decreased interactio
129	no effect on phosphorylation but loss of interaction with ywhab.
164	in yap-4sa; prevents phosphorylation by lats1 and lats2, promoting retention in the nucleus; when associated with a-61;
199	loss of interaction with erbb4, loss of transcriptional coactivation function toward ctf and reduced interaction with pr
202	loss of interaction with erbb4, loss of transcriptional coactivation function toward ctf and reduced interaction with pr
217	no effect on interaction with prrg4.
258	reduced interaction with prrg4; when associated with a-261.
261	reduced interaction with prrg4; when associated with a-258.
397	loss of phosphorylation by lats1. loss of phosphorylation by prpk4; when associated with a-61, a-109, a-164.
407	enhanced interaction with tp73.

Function

Pathways and Gene Ontology

Reactome pathways

13 pathways

ID	Pathway
R-HSA-1251985	Nuclear signaling by ERBB4
R-HSA-2028269	Signaling by Hippo
R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression
R-HSA-8939236	RUNX1 regulates transcription of genes involved in differentiation of HSCs
R-HSA-8940973	RUNX2 regulates osteoblast differentiation
R-HSA-8951671	RUNX3 regulates YAP1-mediated transcription
R-HSA-9619665	EGR2 and SOX10-mediated initiation of Schwann cell myelination
R-HSA-9725554	Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin
R-HSA-9796292	Formation of axial mesoderm
R-HSA-9819196	Zygotic genome activation (ZGA)
R-HSA-9860927	Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
R-HSA-9909649	Regulation of PD-L1(CD274) transcription
R-HSA-9925563	Developmental Lineage of Pancreatic Ductal Cells

MSigDB gene sets: 508 (showing top): GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_RESPONSE_TO_IONIZING_RADIATION, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GOBP_SOMATIC_STEM_CELL_POPULATION_MAINTENANCE, GOBP_REGULATION_OF_EPITHELIAL_CELL_APOPTOTIC_PROCESS, GOBP_LUNG_EPITHELIUM_DEVELOPMENT, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_METANEPHROS_DEVELOPMENT, GOBP_CIRCULATORY_SYSTEM_PROCESS, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_EPITHELIAL_CELL_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_FAT_CELL_DIFFERENTIATION

GO Biological Process (63): negative regulation of transcription by RNA polymerase II (GO:0000122), cell morphogenesis (GO:0000902), vasculogenesis (GO:0001570), trophectodermal cell differentiation (GO:0001829), tissue homeostasis (GO:0001894), glandular epithelial cell differentiation (GO:0002067), heart process (GO:0003015), embryonic heart tube morphogenesis (GO:0003143), DNA damage response (GO:0006974), positive regulation of gene expression (GO:0010628), negative regulation of gene expression (GO:0010629), regulation of keratinocyte proliferation (GO:0010837), keratinocyte differentiation (GO:0030216), positive regulation of cell growth (GO:0030307), negative regulation of epithelial cell differentiation (GO:0030857), polarized epithelial cell differentiation (GO:0030859), notochord development (GO:0030903), response to progesterone (GO:0032570), somatic stem cell population maintenance (GO:0035019), organ growth (GO:0035265), hippo signaling (GO:0035329), wound healing (GO:0042060), negative regulation of fat cell differentiation (GO:0045599), positive regulation of osteoblast differentiation (GO:0045669), positive regulation of Notch signaling pathway (GO:0045747), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), paraxial mesoderm development (GO:0048339), lateral mesoderm development (GO:0048368), epithelial cell proliferation (GO:0050673), positive regulation of epithelial cell proliferation (GO:0050679), regulation of neurogenesis (GO:0050767), positive regulation of cardiac muscle cell proliferation (GO:0060045), canonical Wnt signaling pathway (GO:0060070), bud elongation involved in lung branching (GO:0060449), lung epithelial cell differentiation (GO:0060487), intestinal epithelial cell development (GO:0060576), cardiac muscle tissue regeneration (GO:0061026), protein-containing complex assembly (GO:0065003), interleukin-6-mediated signaling pathway (GO:0070102)

GO Molecular Function (9): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), chromatin binding (GO:0003682), transcription coregulator activity (GO:0003712), transcription coactivator activity (GO:0003713), transcription corepressor activity (GO:0003714), proline-rich region binding (GO:0070064), DNA-binding transcription factor binding (GO:0140297), protein binding (GO:0005515)

GO Cellular Component (14): female germ cell nucleus (GO:0001674), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), mitochondrion (GO:0005739), cytosol (GO:0005829), plasma membrane (GO:0005886), cell-cell junction (GO:0005911), bicellular tight junction (GO:0005923), cell junction (GO:0030054), TEAD-YAP complex (GO:0140552), transcription regulator complex (GO:0005667), membrane (GO:0016020), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-13 pathways:

Category	Pathways
Signaling by ERBB4	1
Signal Transduction	1
Generic Transcription Pathway	1
Transcriptional regulation by RUNX1	1
RUNX2 regulates bone development	1
Transcriptional regulation by RUNX3	1
Nervous system development	1
Developmental Cell Lineages of the Integumentary System	1
Gastrulation	1
Maternal to zygotic transition (MZT)	1
Response of endothelial cells to shear stress	1
Regulation of PD-L1(CD274) expression	1
Developmental Cell Lineages of the Exocrine Pancreas	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
negative regulation of DNA-templated transcription	2
cell differentiation	2
gene expression	2
regulation of gene expression	2
epithelial cell differentiation	2
binding	2
transcription coregulator activity	2
intracellular membrane-bounded organelle	2
cytoplasm	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
anatomical structure morphogenesis	1
blood vessel morphogenesis	1
blastocyst formation	1
multicellular organismal-level homeostasis	1
anatomical structure homeostasis	1
columnar/cuboidal epithelial cell differentiation	1
circulatory system process	1
heart morphogenesis	1
embryonic heart tube development	1
embryonic organ morphogenesis	1
embryonic morphogenesis	1
epithelial tube morphogenesis	1
cellular response to stress	1
positive regulation of macromolecule biosynthetic process	1
negative regulation of macromolecule biosynthetic process	1
keratinocyte proliferation	1
regulation of epithelial cell proliferation	1
epidermal cell differentiation	1
skin development	1
regulation of cell growth	1
cell growth	1
positive regulation of growth	1
positive regulation of cellular process	1
regulation of epithelial cell differentiation	1
negative regulation of cell differentiation	1
morphogenesis of a polarized epithelium	1
embryonic organ development	1
response to steroid hormone	1

Protein interactions and networks

STRING

4160 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
YAP1	TEAD1	P28347	999
YAP1	TEAD4	Q15561	992
YAP1	CTNNB1	P35222	987
YAP1	TBX5	Q99593	984
YAP1	LATS1	O95835	974
YAP1	TEAD2	Q15562	965
YAP1	YES1	P07947	936
YAP1	ERBB4	Q15303	915
YAP1	JUN	P05412	906
YAP1	AMOT	Q4VCS5	906
YAP1	TEAD3	Q99594	882
YAP1	PRRG2	O14669	861
YAP1	POU5F1	P31359	853
YAP1	PTPN14	Q15678	850
YAP1	TP73	O15350	843

IntAct

516 interactions, top by confidence:

A	B	Type	Score
AXIN1	CTNNB1	psi-mi:“MI:0914”(association)	0.940
YAP1	TEAD1	psi-mi:“MI:0915”(physical association)	0.940
TEAD1	YAP1	psi-mi:“MI:0915”(physical association)	0.940
YAP1	TEAD4	psi-mi:“MI:0915”(physical association)	0.930
TEAD4	YAP1	psi-mi:“MI:0407”(direct interaction)	0.930
YAP1	YWHAB	psi-mi:“MI:0915”(physical association)	0.910
YWHAZ	YAP1	psi-mi:“MI:0915”(physical association)	0.880
YWHAZ	YAP1	psi-mi:“MI:0403”(colocalization)	0.880
YAP1	LATS1	psi-mi:“MI:0407”(direct interaction)	0.880
YAP1	YWHAE	psi-mi:“MI:0915”(physical association)	0.840
YWHAE	YAP1	psi-mi:“MI:0915”(physical association)	0.840
YWHAQ	WDR62	psi-mi:“MI:0914”(association)	0.830
TEAD2	YAP1	psi-mi:“MI:0407”(direct interaction)	0.820
PRRG4	YAP1	psi-mi:“MI:0407”(direct interaction)	0.820
TEAD2	YAP1	psi-mi:“MI:2364”(proximity)	0.820
YAP1	PRRG4	psi-mi:“MI:0407”(direct interaction)	0.820
YAP1	TP73	psi-mi:“MI:0407”(direct interaction)	0.730

BioGRID (2066): ABL1 (Affinity Capture-Western), YAP1 (Biochemical Activity), TP73 (Affinity Capture-Western), YAP1 (Affinity Capture-Western), YAP1 (Affinity Capture-Western), YAP1 (Affinity Capture-RNA), YAP1 (Affinity Capture-RNA), YAP1 (Affinity Capture-RNA), YAP1 (Protein-peptide), YAP1 (Affinity Capture-MS), YAP1 (Affinity Capture-MS), YAP1 (Affinity Capture-MS), YAP1 (Affinity Capture-MS), YAP1 (Affinity Capture-MS), YAP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A8C0NGY6, A0A8I3PQN6, A1L1N5, A2BEA6, A2ICN5, A2VDZ3, A4QNP0, D6C652, F1LYL9, H2LBU8, O18896, O94842, P19484, P23899, P27889, P35680, P46936, P46937, P46938, P48436, P61753, P61754, Q02078, Q03365, Q04887, Q0P5K4, Q1L8J7, Q2EJA0, Q2LE08, Q2MJT0, Q32NJ6, Q4VYR7, Q571K4, Q5R6A9, Q5RER5, Q5XGD9, Q62431, Q6GQD7, Q7YRJ7, Q7ZXH3

Diamond homologs: A0A8C0NGY6, A0A8I3PQN6, A1A5G4, A1CQG2, A1D3C5, A2QQ28, A4IIJ3, B0XQ72, B3LWS4, B3P3M8, B4HEJ6, B4K6I9, B4M5X4, B4NAD3, B4PSQ2, B8N7E5, D6C652, G0S9J5, H2LBU8, O14326, O88382, P39940, P46934, P46935, P46936, P46937, P46938, Q0CCL1, Q19404, Q1L8J7, Q2EJA0, Q2UBP1, Q32NJ6, Q45VV3, Q4L1J4, Q4WTF3, Q54T86, Q5BDP1, Q5F488, Q5RBF2

SIGNOR signaling

111 interactions.

A	Effect	B	Mechanism
YAP1	down-regulates	RUNX2	binding
ABL1	up-regulates	YAP1	phosphorylation
14-3-3	down-regulates	YAP1	binding
AMOT	down-regulates	YAP1	relocalization
YAP1	up-regulates	TP73	binding
LATS1	down-regulates	YAP1	phosphorylation
LATS2	down-regulates	YAP1	phosphorylation
YAP1	“up-regulates quantity by expression”	BMP4	“transcriptional regulation”
YAP1	down-regulates	FBXO32
YAP1	“up-regulates quantity by expression”	FSTL3	“transcriptional regulation”
YAP1	down-regulates	MYF6
YAP1	down-regulates	Apoptosis
YAP1	up-regulates	Proliferation
YAP1	down-regulates	DVL1	binding
BTRC	down-regulates	YAP1	ubiquitination
CSNK1D	down-regulates	YAP1	phosphorylation
CSNK1E	down-regulates	YAP1	phosphorylation
CTNNA1	down-regulates	YAP1	binding
CTNNA2	down-regulates	YAP1	binding
dobutamine	down-regulates	YAP1
YAP1	up-regulates	SMAD1	binding
YAP1	up-regulates	TEAD1	binding
YAP1	up-regulates	TEAD2	binding
YAP1	up-regulates	TEAD3	binding
YAP1	up-regulates	TEAD4	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 154 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	56.1×	3e-09
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	49.5×	5e-09
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	49.5×	5e-09
YAP1- and WWTR1 (TAZ)-stimulated gene expression	5	40.1×	4e-06
Activation of BH3-only proteins	7	36.6×	4e-08
RHO GTPases activate PKNs	8	26.7×	4e-08
Intrinsic Pathway for Apoptosis	7	21.6×	2e-06
FOXO-mediated transcription	6	21.2×	1e-05

GO biological processes:

GO term	Partners	Fold	FDR
hippo signaling	7	39.1×	3e-07
embryonic organ development	5	18.4×	1e-03
protein targeting	5	14.0×	4e-03
substantia nigra development	5	14.0×	4e-03
positive regulation of miRNA transcription	6	13.3×	1e-03
intracellular protein localization	9	7.2×	1e-03
transcription by RNA polymerase II	10	5.4×	3e-03

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

143 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	2
Uncertain significance	76
Likely benign	28
Benign	15

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
120326	NM_001130145.3(YAP1):c.370C>T (p.Arg124Ter)	Pathogenic
120327	NM_001130145.3(YAP1):c.1066G>T (p.Glu356Ter)	Pathogenic
1686307	NM_001130145.3(YAP1):c.257T>C (p.Met86Thr)	Pathogenic
800330	NM_001130145.3(YAP1):c.488C>G (p.Ser163Cys)	Likely pathogenic
982760	NM_001130145.3(YAP1):c.1196_1199del (p.Asp399fs)	Likely pathogenic

SpliceAI

2339 predictions. Top by Δscore:

Variant	Effect	Δscore
11:102111167:CAGG:C	donor_loss	1.0000
11:102111169:GGT:G	donor_loss	1.0000
11:102111171:T:A	donor_loss	1.0000
11:102114395:G:GG	donor_gain	1.0000
11:102162451:CTTA:C	acceptor_loss	1.0000
11:102162454:A:AC	acceptor_loss	1.0000
11:102162454:A:AG	acceptor_gain	1.0000
11:102162455:G:GT	acceptor_gain	1.0000
11:102162455:GT:G	acceptor_gain	1.0000
11:102162455:GTC:G	acceptor_gain	1.0000
11:102162455:GTCA:G	acceptor_gain	1.0000
11:102162455:GTCAC:G	acceptor_gain	1.0000
11:102162572:G:C	donor_loss	1.0000
11:102162572:G:GG	donor_gain	1.0000
11:102162573:T:A	donor_loss	1.0000
11:102205886:A:AG	acceptor_gain	1.0000
11:102205887:T:G	acceptor_gain	1.0000
11:102205888:TTCA:T	acceptor_loss	1.0000
11:102205889:TCAGC:T	acceptor_loss	1.0000
11:102205890:CA:C	acceptor_loss	1.0000
11:102205891:A:AG	acceptor_gain	1.0000
11:102205891:AG:A	acceptor_loss	1.0000
11:102205892:G:GA	acceptor_gain	1.0000
11:102205892:GC:G	acceptor_gain	1.0000
11:102205892:GCC:G	acceptor_gain	1.0000
11:102205892:GCCA:G	acceptor_gain	1.0000
11:102205892:GCCAT:G	acceptor_gain	1.0000
11:102206072:C:T	donor_gain	1.0000
11:102206072:CAG:C	donor_loss	1.0000
11:102206073:AGG:A	donor_loss	1.0000

AlphaMissense

3307 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:102111018:T:A	V57D	1.000
11:102111042:T:A	L65Q	1.000
11:102111042:T:C	L65P	1.000
11:102111051:T:A	L68H	1.000
11:102111051:T:C	L68P	1.000
11:102111053:T:A	F69I	1.000
11:102111053:T:C	F69L	1.000
11:102111054:T:C	F69S	1.000
11:102111054:T:G	F69C	1.000
11:102111055:C:A	F69L	1.000
11:102111055:C:G	F69L	1.000
11:102111059:G:C	A71P	1.000
11:102111063:T:A	V72D	1.000
11:102111120:T:A	L91Q	1.000
11:102111120:T:C	L91P	1.000
11:102111122:C:A	P92T	1.000
11:102111122:C:T	P92S	1.000
11:102111123:C:A	P92H	1.000
11:102111123:C:T	P92L	1.000
11:102111131:T:C	F95L	1.000
11:102111132:T:C	F95S	1.000
11:102111132:T:G	F95C	1.000
11:102111133:C:A	F95L	1.000
11:102111133:C:G	F95L	1.000
11:102111134:T:C	F96L	1.000
11:102111136:C:A	F96L	1.000
11:102111136:C:G	F96L	1.000
11:102114147:A:C	S109R	1.000
11:102114149:T:A	S109R	1.000
11:102114149:T:G	S109R	1.000

dbSNP variants (sampled 300 via entrez): RS1000011885 (11:102158688 T>C), RS1000015793 (11:102188698 C>T), RS1000021317 (11:102112709 A>G), RS1000046668 (11:102188916 A>G), RS1000052598 (11:102228363 G>A,T), RS1000083940 (11:102190573 T>A,C,G), RS1000088761 (11:102152234 A>G), RS1000105059 (11:102144068 AG>A), RS1000145477 (11:102218137 A>G), RS1000146544 (11:102230316 T>C), RS1000230647 (11:102212374 A>G), RS1000252171 (11:102213600 T>C), RS1000260003 (11:102118140 T>C), RS1000276788 (11:102129863 C>G,T), RS1000288051 (11:102167242 T>G)

Disease associations

OMIM: gene MIM:606608 | disease phenotypes: MIM:120433, MIM:254500

GenCC curated gene-disease

Disease	Classification	Inheritance
uveal coloboma-cleft lip and palate-intellectual disability	Strong	Autosomal dominant

Mondo (3): uveal coloboma-cleft lip and palate-intellectual disability (MONDO:0007355), coloboma (MONDO:0001476), plasma cell myeloma (MONDO:0009693)

Orphanet (4): Uveal coloboma-cleft lip and palate-intellectual disability (Orphanet:1473), OBSOLETE: Ocular coloboma (Orphanet:194), Multiple myeloma (Orphanet:29073), AL amyloidosis (Orphanet:85443)

HPO phenotypes

21 total (21 of 21 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000175	Cleft palate
HP:0000204	Cleft upper lip
HP:0000365	Hearing impairment
HP:0000407	Sensorineural hearing impairment
HP:0000486	Strabismus
HP:0000501	Glaucoma
HP:0000505	Visual impairment
HP:0000508	Ptosis
HP:0000518	Cataract
HP:0000541	Retinal detachment
HP:0000567	Chorioretinal coloboma
HP:0000568	Microphthalmia
HP:0000612	Iris coloboma
HP:0000627	Posterior embryotoxon
HP:0000639	Nystagmus
HP:0000648	Optic atrophy
HP:0000790	Hematuria
HP:0001249	Intellectual disability
HP:0003577	Congenital onset
HP:0007957	Corneal opacity

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST000895_4	Whole-brain volume (Alzheimer’s disease interaction)	1.000000e-06
GCST001634_6	Polycystic ovary syndrome	1.000000e-22
GCST001875_7	Pubertal anthropometrics	2.000000e-06
GCST001942_2	Prostate cancer	2.000000e-11
GCST003144_3	Polycystic ovary syndrome	8.000000e-11
GCST003720_5	Migraine	2.000000e-08
GCST005946_19	Cleft palate	3.000000e-08
GCST005946_20	Cleft palate	2.000000e-07
GCST005947_12	Cleft palate	2.000000e-07
GCST005947_13	Cleft palate	6.000000e-07
GCST006629_31	Pulse pressure	3.000000e-17
GCST006979_418	Heel bone mineral density	1.000000e-09
GCST007089_9	Polycystic ovary syndrome	5.000000e-11
GCST007269_119	Pulse pressure	6.000000e-15
GCST007856_3	Colorectal cancer or advanced adenoma	3.000000e-06
GCST008363_86	Offspring birth weight	7.000000e-13
GCST012490_506	Femur bone mineral density x serum urate levels interaction	3.000000e-08
GCST90002405_293	Reticulocyte count	4.000000e-10
GCST90013406_14	Liver enzyme levels (alkaline phosphatase)	1.000000e-11

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0005089	whole-brain volume
EFO:0005763	pulse pressure measurement
EFO:0009270	heel bone mineral density
EFO:0004344	birth weight
EFO:0005939	parental genotype effect measurement
EFO:0004531	urate measurement
EFO:0007986	reticulocyte count
EFO:0004533	alkaline phosphatase measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D003103	Coloboma	C11.250.110; C11.270.147; C16.131.384.282
D009101	Multiple Myeloma	C04.557.595.500; C14.907.454.460; C15.378.147.780.650; C15.378.463.515.460; C20.683.515.845; C20.683.780.650
C535971	Coloboma, cleft lip-palate and mental retardation syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (7): CHEMBL3334415 (SINGLE PROTEIN), CHEMBL3430909 (PROTEIN-PROTEIN INTERACTION), CHEMBL5465250 (PROTEIN COMPLEX), CHEMBL5465398 (PROTEIN-PROTEIN INTERACTION), CHEMBL5465558 (PROTEIN-PROTEIN INTERACTION), CHEMBL6066034 (PROTEIN-PROTEIN INTERACTION), CHEMBL6066144 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1820453	YAP1		0.00	0
rs10895256	YAP1		0.00	0

Binding affinities (BindingDB)

104 measured of 110 human assays (110 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
US12083101, Example 71b	IC50	1 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 110	IC50	1 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 112	IC50	1 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 147	IC50	1 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 170	IC50	1 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 12	IC50	1.5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 38	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 56b	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 66a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 66b	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 67a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 71a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 94a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 99	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 100a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 104b	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 108	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 113	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 115a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 115b	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 121	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 126	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 151	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 152	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 171	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 31	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 33	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 51	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 57b	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 86	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 94b	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 102a	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 120	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 143	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 146	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 8	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 58b	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 69b	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 85a	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 97	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 111	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 140a	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 150	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 164	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 49	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 69a	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 96	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 98	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 103	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 141	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors

ChEMBL bioactivities

80 potent at pChembl≥5 of 108 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.99	IC50	1.02	nM	CHEMBL5198469
7.82	Kd	15	nM	CHEMBL3335461
7.75	Kd	18	nM	CHEMBL3335453
7.60	IC50	25	nM	CHEMBL3335461
7.41	Kd	39	nM	CHEMBL3335452
7.39	IC50	41	nM	CHEMBL3335458
7.38	IC50	42	nM	CHEMBL3335453
7.12	IC50	75	nM	CHEMBL3335463
6.82	IC50	150	nM	CHEMBL3335452
6.68	Kd	211	nM	CHEMBL3335451
6.66	IC50	220	nM	CHEMBL4439905
6.51	IC50	310	nM	CHEMBL3335456
6.48	IC50	328	nM	CHEMBL4474533
6.47	IC50	340	nM	CHEMBL3335457
6.47	Kd	340	nM	CHEMBL5429947
6.46	IC50	350	nM	CHEMBL3335459
6.43	IC50	370	nM	CHEMBL3335454
6.42	IC50	380	nM	CHEMBL3335460
6.41	IC50	391	nM	CHEMBL5406194
6.34	IC50	454	nM	CHEMBL5398453
6.28	IC50	530	nM	CHEMBL3335462
6.28	IC50	528	nM	CHEMBL4541982
6.21	IC50	620	nM	CHEMBL3335455
6.13	Kd	738	nM	CHEMBL2004687
6.05	IC50	900	nM	CHEMBL5429883
6.05	IC50	900	nM	CHEMBL1719036
6.00	IC50	1000	nM	CHEMBL4547935
6.00	IC50	1000	nM	CHEMBL4469116
6.00	IC50	1000	nM	CHEMBL4558314
6.00	IC50	1000	nM	CHEMBL4546804
6.00	IC50	1000	nM	CHEMBL4520244
6.00	IC50	1000	nM	CHEMBL4572362
6.00	IC50	1000	nM	CHEMBL4474075
6.00	IC50	1000	nM	CHEMBL4519785
6.00	IC50	990	nM	CHEMBL4476836
5.96	IC50	1100	nM	CHEMBL5393763
5.96	IC50	1100	nM	CHEMBL1499544
5.85	IC50	1400	nM	CHEMBL1719036
5.85	IC50	1400	nM	CHEMBL5420439
5.85	IC50	1400	nM	CHEMBL5423389
5.82	IC50	1500	nM	CHEMBL3335450
5.82	IC50	1500	nM	CHEMBL5403233
5.77	IC50	1700	nM	CHEMBL3335451
5.72	IC50	1900	nM	CHEMBL5406070
5.70	IC50	2000	nM	CHEMBL1349646
5.66	IC50	2200	nM	CHEMBL4460512
5.66	IC50	2200	nM	CHEMBL5423389
5.64	IC50	2300	nM	CHEMBL5423389
5.62	IC50	2400	nM	CHEMBL4476277
5.58	IC50	2600	nM	CHEMBL5421684

PubChem BioAssay actives

68 with measured affinity, of 336 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-methyl-3-(1-methylimidazol-4-yl)-4-[4-(trifluoromethyl)anilino]benzenesulfonamide	2007256: Inhibition of YAP (unknown origin) incubated for 24 hrs by Promega Dual-Luciferase Reporter Assay	ic50	0.0010	uM
2-[(2S,3S)-5-chloro-6-fluoro-3-methyl-2-(methylaminomethyl)-2-phenyl-3H-1-benzofuran-4-yl]-3-fluoro-4-methoxybenzamide	2007263: Inhibition of Avi-His-tagged human TEAD4 (217 to 434 residues)/N-biotinylated-N-terminal Cy5-labelled human YAP (60 to 100 residues) incubated for 1 hr by TR FRET assay	ic50	0.0020	uM
2-[(2S,3S)-2-(aminomethyl)-5-chloro-6-fluoro-3-methyl-2-phenyl-3H-1-benzofuran-4-yl]-3-fluoro-4-(2-methoxyethoxy)benzamide	2007263: Inhibition of Avi-His-tagged human TEAD4 (217 to 434 residues)/N-biotinylated-N-terminal Cy5-labelled human YAP (60 to 100 residues) incubated for 1 hr by TR FRET assay	ic50	0.0020	uM
2-[(2S,3R)-2-(aminomethyl)-5-chloro-6-fluoro-3-(hydroxymethyl)-2-phenyl-3H-1-benzofuran-4-yl]-3-fluoro-4-methoxybenzamide	2007263: Inhibition of Avi-His-tagged human TEAD4 (217 to 434 residues)/N-biotinylated-N-terminal Cy5-labelled human YAP (60 to 100 residues) incubated for 1 hr by TR FRET assay	ic50	0.0020	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-(3-chlorophenyl)propanoyl]amino]-6-(4-aminobutyl)-24-benzyl-3-butyl-9-(3-carbamimidamidopropyl)-27-(hydroxymethyl)-30-methyl-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164243: Inhibition of YAP/ GST-TEAD1 interaction in human Bel-7404 cells by GST pull-down assay	kd	0.0150	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-6-(4-aminobutyl)-24-benzyl-9-[3-(diaminomethylideneamino)propyl]-27-(hydroxymethyl)-30-methyl-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-3-pentyl-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164243: Inhibition of YAP/ GST-TEAD1 interaction in human Bel-7404 cells by GST pull-down assay	kd	0.0180	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-6-(4-aminobutyl)-24-benzyl-3-butyl-9-[3-(diaminomethylideneamino)propyl]-27-(hydroxymethyl)-30-methyl-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164243: Inhibition of YAP/ GST-TEAD1 interaction in human Bel-7404 cells by GST pull-down assay	kd	0.0390	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]heptanoyl]amino]-6-(4-aminobutyl)-24-benzyl-3-butyl-9-[3-(diaminomethylideneamino)propyl]-27-(hydroxymethyl)-30-methyl-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164242: Inhibition of YAP/ GST-TEAD1 (unknown origin) interaction by surface plasmon resonance assay	ic50	0.0410	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-6-(4-aminobutyl)-3-butyl-9-[3-(diaminomethylideneamino)propyl]-24-[(4-fluorophenyl)methyl]-27-(hydroxymethyl)-30-methyl-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164242: Inhibition of YAP/ GST-TEAD1 (unknown origin) interaction by surface plasmon resonance assay	ic50	0.0750	uM
N-methylsulfonyl-5-[4-(trifluoromethyl)phenoxy]naphthalene-2-carboxamide	2007265: Inhibition of YAP in HEK293T cells incubated for 24 hrs by Promega Dual-Luciferase Reporter Assay	ic50	0.1000	uM
N-(cyanomethyl)-5-[4-(trifluoromethyl)phenoxy]naphthalene-2-carboxamide	2007265: Inhibition of YAP in HEK293T cells incubated for 24 hrs by Promega Dual-Luciferase Reporter Assay	ic50	0.1000	uM
5-(3-chlorophenoxy)-N-propan-2-ylnaphthalene-2-carboxamide	2007265: Inhibition of YAP in HEK293T cells incubated for 24 hrs by Promega Dual-Luciferase Reporter Assay	ic50	0.1000	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-6-(4-aminobutyl)-24-benzyl-3-butyl-9-(3-carbamimidamidopropyl)-30-(carboxymethyl)-27-(hydroxymethyl)-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164243: Inhibition of YAP/ GST-TEAD1 interaction in human Bel-7404 cells by GST pull-down assay	kd	0.2110	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-6-(4-aminobutyl)-24-benzyl-9-[3-(diaminomethylideneamino)propyl]-27-(hydroxymethyl)-30-methyl-3-(4-methylpentyl)-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164242: Inhibition of YAP/ GST-TEAD1 (unknown origin) interaction by surface plasmon resonance assay	ic50	0.3100	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-6-(4-aminobutyl)-24-benzyl-3-butyl-9-[3-(diaminomethylideneamino)propyl]-27-(hydroxymethyl)-30-methyl-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164242: Inhibition of YAP/ GST-TEAD1 (unknown origin) interaction by surface plasmon resonance assay	ic50	0.3400	uM
3-[(3S,6S,9S,12S,15S,18S,21S,24S,27S,30S)-21-(4-aminobutyl)-3,12-bis[(4-hydroxyphenyl)methyl]-24-(1H-imidazol-5-ylmethyl)-6,27-dimethyl-9,15-bis(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29-decaoxo-1,4,7,10,13,16,19,22,25,28-decazabicyclo[28.3.0]tritriacontan-18-yl]propanoic acid	2007250: Binding affinity to N-terminal YAP ( 1 to 291 residues) (unknown origin) expressed in Escherichia coli Rosetta cells assessed as dissociation constant by yeast surface titration method	kd	0.3400	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-6-(4-aminobutyl)-24-benzyl-3-butyl-9-(3-carbamimidamidopropyl)-27-(hydroxymethyl)-30-methyl-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164242: Inhibition of YAP/ GST-TEAD1 (unknown origin) interaction by surface plasmon resonance assay	ic50	0.3500	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-6-(4-aminobutyl)-24-benzyl-9-[3-(diaminomethylideneamino)propyl]-3-hexyl-27-(hydroxymethyl)-30-methyl-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164242: Inhibition of YAP/ GST-TEAD1 (unknown origin) interaction by surface plasmon resonance assay	ic50	0.3700	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-(2-chlorophenyl)propanoyl]amino]-6-(4-aminobutyl)-24-benzyl-3-butyl-9-(3-carbamimidamidopropyl)-27-(hydroxymethyl)-30-methyl-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164242: Inhibition of YAP/ GST-TEAD1 (unknown origin) interaction by surface plasmon resonance assay	ic50	0.3800	uM
3-(4-bromophenyl)-2-(dimethylamino)-N-(1-pyridin-2-ylethyl)thieno[2,3-d]imidazole-5-carboxamide	2007256: Inhibition of YAP (unknown origin) incubated for 24 hrs by Promega Dual-Luciferase Reporter Assay	ic50	0.3910	uM
methyl 2-(cyclohexylamino)-5-sulfamoylbenzoate	2007256: Inhibition of YAP (unknown origin) incubated for 24 hrs by Promega Dual-Luciferase Reporter Assay	ic50	0.4540	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-6-(4-aminobutyl)-24-benzyl-3-butyl-9-(3-carbamimidamidopropyl)-27-(hydroxymethyl)-30-methyl-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164242: Inhibition of YAP/ GST-TEAD1 (unknown origin) interaction by surface plasmon resonance assay	ic50	0.5300	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-6-(4-aminobutyl)-24-benzyl-9-[3-(diaminomethylideneamino)propyl]-27-(hydroxymethyl)-30-methyl-3-(3-methylbutyl)-12-(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164242: Inhibition of YAP/ GST-TEAD1 (unknown origin) interaction by surface plasmon resonance assay	ic50	0.6200	uM
4-(3,4-dimethoxyphenyl)-2-phenyl-5,7-dihydropyrido[3,2-d][1]benzazepin-6-one	2123118: Binding affinity to YAP (unknown origin) assessed as dissociation constant by SPR analysis	kd	0.7380	uM
2-(3-chloro-N-(2-chloroacetyl)anilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide	1977251: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 48 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	0.9000	uM
3-[(2-chloroacetyl)amino]-1-benzofuran-2-carboxamide	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	0.9000	uM
2-chloro-1-[3-(4-methylphenyl)sulfonyl-2-phenylimidazolidin-1-yl]ethanone	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	1.0000	uM
2-(3-chloro-N-(2-chloroacetyl)-4-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	1.1000	uM
2-chloro-1-[3-(2,3-dimethoxyphenyl)-5-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]ethanone	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	1.1000	uM
2-chloro-N-[2-(4-chlorophenyl)sulfanylethyl]acetamide	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	1.4000	uM
2-chloro-1-[3-(furan-2-yl)-5-(4-methylphenyl)-3,4-dihydropyrazol-2-yl]ethanone	1977251: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 48 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	1.4000	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-6-(4-aminobutyl)-24-benzyl-9-[3-(diaminomethylideneamino)propyl]-27-(hydroxymethyl)-30-methyl-3,12-bis(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164242: Inhibition of YAP/ GST-TEAD1 (unknown origin) interaction by surface plasmon resonance assay	ic50	1.5000	uM
1-[5-(4-bromophenyl)-3-(4-fluorophenyl)-3,4-dihydropyrazol-2-yl]-2-chloroethanone	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	1.5000	uM
2-chloro-1-[3-(4-methylphenyl)sulfonylimidazolidin-1-yl]ethanone	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	1.9000	uM
2-chloro-1-(12-methyl-1,4-diazatetracyclo[7.6.1.05,16.010,15]hexadeca-9(16),10(15),11,13-tetraen-4-yl)ethanone	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	2.0000	uM
2-chloro-1-[3-(2,3-dimethoxyphenyl)-5-(thiophen-2-ylmethyl)-3,4-dihydropyrazol-2-yl]ethanone	1977251: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 48 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	2.6000	uM
2-chloro-1-[3-(4-methylphenyl)-5-thiophen-2-yl-3,4-dihydropyrazol-2-yl]ethanone	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	3.8000	uM
2-(4-chloro-N-(2-chloroacetyl)anilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	4.0000	uM
[4-[[(2-chloroacetyl)-[(4-fluorophenyl)methyl]amino]methyl]phenyl] ethanesulfonate	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	4.2000	uM
2-chloro-1-[2-[3-(trifluoromethyl)anilino]phenyl]ethanone	2007275: Inhibition of FAM-labelled GST-tagged full-length YAP (60 to 99 residues)(unknown origin)/N-terminal His-tagged TEAD2(217 to 447 residues) (unknown origin)) expressed in Escherichia coli BL21 (DE3) cells by fluorescence polarization assay	ic50	4.3000	uM
2-[(2-chloroacetyl)-[(4-methylphenyl)methyl]amino]-N-cycloheptyl-2-(4-methoxyphenyl)acetamide	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	4.4000	uM
1-(2-chloroacetyl)-N-phenylpiperidine-4-carboxamide	1977251: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 48 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	4.7000	uM
2-chloro-1-(3,5-dithiophen-2-yl-3,4-dihydropyrazol-2-yl)ethanone	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	4.7000	uM
2-[(2-chloroacetyl)-(thiophen-2-ylmethyl)amino]-N-cycloheptyl-2-(4-methoxyphenyl)acetamide	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	4.8000	uM
2-chloro-1-[4-[(E)-2-phenylethenyl]sulfonylpiperazin-1-yl]ethanone	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	4.9000	uM
2-[(2-chloroacetyl)-[(4-methoxyphenyl)methyl]amino]-N-cycloheptyl-2-(4-methoxyphenyl)acetamide	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	5.5000	uM
1-[3-(1H-benzimidazol-2-yl)-5-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-2-chloroethanone	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	5.8000	uM
2-chloro-1-(3,5-diphenyl-3,4-dihydropyrazol-2-yl)ethanone	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	5.9000	uM
2-chloro-1-[5-(4-chlorophenyl)-3-(furan-2-yl)-3,4-dihydropyrazol-2-yl]ethanone	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	6.0000	uM
(4S)-4-[[(2S)-1-[(2S)-1-[(2S)-2-[[(3S,6S,9S,12S,15S,21R,24S,27S,30S,33S)-15-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-6-(4-aminobutyl)-24-benzyl-9-(3-carbamimidamidopropyl)-30-(carboxymethyl)-27-(hydroxymethyl)-3,12-bis(2-methylpropyl)-2,5,8,11,14,23,26,29,32-nonaoxo-18,19-dithia-1,4,7,10,13,22,25,28,31-nonazabicyclo[31.3.0]hexatriacontane-21-carbonyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid	1164242: Inhibition of YAP/ GST-TEAD1 (unknown origin) interaction by surface plasmon resonance assay	ic50	6.9000	uM

CTD chemical–gene interactions

100 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects cotreatment, increases expression, affects expression	7
Verteporfin	decreases reaction, increases activity, increases expression, decreases activity, decreases expression	5
XMU-MP-1	decreases phosphorylation, decreases expression, decreases reaction, increases phosphorylation, increases expression	4
Cisplatin	decreases expression, increases expression, increases cleavage, decreases phosphorylation, increases reaction (+5 more)	4
bisphenol A	affects reaction, increases lipidation, decreases reaction, increases localization, decreases expression (+1 more)	3
trichostatin A	affects cotreatment, increases expression	3
Tetrachlorodibenzodioxin	affects reaction, affects response to substance, affects cotreatment, increases expression	3
Cadmium Chloride	affects binding, increases reaction, decreases activity, decreases phosphorylation, increases localization (+3 more)	3
sodium arsenite	increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Gemcitabine	increases activity, increases phosphorylation, affects reaction, increases cleavage, affects response to substance (+3 more)	2
Air Pollutants	affects cotreatment, decreases expression, increases abundance, increases oxidation, affects methylation	2
Doxorubicin	decreases phosphorylation, decreases expression, increases expression, increases reaction, affects cotreatment (+1 more)	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Aflatoxin B1	affects cotreatment, decreases expression, increases expression	2
caulerpin	decreases expression, increases phosphorylation	1
afuresertib	decreases phosphorylation	1
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
napabucasin	decreases expression	1
WZ35 compound	decreases expression	1
limonin	affects localization	1
bufotalin	increases expression	1
methylmercuric chloride	increases expression	1
alpha-pinene	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
deoxynivalenol	decreases phosphorylation	1
gingerol	affects localization, affects cotreatment, increases phosphorylation, decreases reaction, increases expression (+1 more)	1
nuciferine	decreases expression, increases phosphorylation, increases reaction, affects reaction	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, increases expression	1
terbufos	increases methylation	1

ChEMBL screening assays

135 unique, capped per target: 135 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4336776	Binding	Induction of YAP nuclear translocation in human A549 cells at 10 uM incubated for 8 hrs by immunofluorescence based confocal microscopy	Discovery of 1,8-disubstituted-[1,2,3]triazolo[4,5-c]quinoline derivatives as a new class of Hippo signaling pathway inhibitors. — Bioorg Med Chem Lett

Cellosaurus cell lines

36 cell lines: 19 cancer cell line, 6 transformed cell line, 4 induced pluripotent stem cell, 3 embryonic stem cell, 2 telomerase immortalized cell line, 2 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A0TX	HGrC1-YAP	Transformed cell line	Female
CVCL_A0TY	HGrC1-YAP(S127A)	Transformed cell line	Female
CVCL_A5LL	H7-YAP1	Embryonic stem cell	Female
CVCL_A5LM	H14-YAP1	Embryonic stem cell	Male
CVCL_A9SX	BL1391	Cancer cell line	Female
CVCL_B5SH	MUSIe002-A-1	Embryonic stem cell	Male
CVCL_B9CJ	Abcam MCF-7 YAP1 KO	Cancer cell line	Female
CVCL_C0FF	MUSIi017-A-1	Induced pluripotent stem cell	Male
CVCL_C0FG	MUSIi017-A-2	Induced pluripotent stem cell	Male
CVCL_C3IS	1321N1 YAP1 KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00104104	PHASE4	COMPLETED	A Multiple Myeloma Trial in Patients With Bone Metastases
NCT00211211	PHASE4	COMPLETED	FREE Study - Fracture Reduction Evaluation
NCT00242528	PHASE4	WITHDRAWN	Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
NCT00257114	PHASE4	COMPLETED	Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00352703	PHASE4	COMPLETED	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
NCT00361140	PHASE4	COMPLETED	Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
NCT00622505	PHASE4	COMPLETED	Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
NCT00652041	PHASE4	COMPLETED	Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
NCT00733538	PHASE4	COMPLETED	Stage I Multiple Myeloma Treatment
NCT01087008	PHASE4	COMPLETED	Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
NCT01249690	PHASE4	UNKNOWN	Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
NCT01410929	PHASE4	WITHDRAWN	Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma
NCT01731886	PHASE4	COMPLETED	Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01868828	PHASE4	UNKNOWN	A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
NCT02268890	PHASE4	COMPLETED	A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
NCT02286830	PHASE4	COMPLETED	Prolonged Protection From Bone Disease in Multiple Myeloma
NCT02559154	PHASE4	UNKNOWN	Modified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02577783	PHASE4	UNKNOWN	PDD vs PAD to Treat Initially Diagnosed MM
NCT02773550	PHASE4	TERMINATED	Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
NCT02958969	PHASE4	COMPLETED	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
NCT03173092	PHASE4	TERMINATED	A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
NCT03619252	PHASE4	COMPLETED	Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
NCT03768960	PHASE4	COMPLETED	A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
NCT03829371	PHASE4	ACTIVE_NOT_RECRUITING	STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT03908138	PHASE4	UNKNOWN	RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
NCT04217967	PHASE4	COMPLETED	Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
NCT04952766	PHASE4	COMPLETED	Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
NCT04989140	PHASE4	UNKNOWN	Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
NCT05183139	PHASE4	WITHDRAWN	A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
NCT05201781	PHASE4	RECRUITING	A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05429515	PHASE4	NOT_YET_RECRUITING	Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
NCT05511428	PHASE4	COMPLETED	Home Based Daratumumab Administration for Patients With Multiple Myeloma
NCT05545202	PHASE4	UNKNOWN	A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
NCT05555329	PHASE4	COMPLETED	Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
NCT05722405	PHASE4	RECRUITING	Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
NCT05855122	PHASE4	UNKNOWN	Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
NCT05944783	PHASE4	NOT_YET_RECRUITING	Bioequivalence Studies of Dasatinib 100 Mg
NCT06057402	PHASE4	RECRUITING	Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06251076	PHASE4	RECRUITING	Plan Development for Giving Teclistamab in the Outpatient Setting